The UK and US have secured a key trade agreement that will ensure zero import taxes on British pharmaceutical exports going into the US market.
The Terms of the Deal
In exchange for the tariff guarantee, the UK has pledged to raise funding on drugs through the NHS. This pledge secures that tariffs on these crucial exports will stay at zero for a timeframe of 36 months.
This agreement is in response to previous warnings to dramatically increase duties on patented pharmaceutical imports, with increases discussed up to one hundred percent.
"This deal with the UK reinforces the international landscape for new treatments and brings long-overdue fairness to U.S.–U.K. medicine commerce," a statement noted.
Economic Impact
Drugs constitute one of the UK's largest goods shipped to the US, which is clearly the primary destination for major British pharmaceutical firms.
Export figures indicate that in the one-year period leading up to last September, the UK exported medicines valued at billions to the US. This figure represented a significant portion of all goods exports in that timeframe.
"This agreement secures jobs, boosts capital expenditure and facilitates the UK to establish itself as a worldwide center for biotech and pharma," a government official remarked.
Key UK Commitments
The pact involves several key changes from the UK:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it judges new treatments to be too expensive by a quarter.
- Increased NHS Spending: There is a goal to increase total public funding on drugs from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The amount manufacturers must pay back to the NHS to prevent overspending will be capped at fifteen percent. Last year, rebates exceeded 20%.
Recent Tensions
This agreement follows a ongoing tension between the sector and the UK government over spending levels and approval rates.
This friction were intensified by arguments that American patients were charged significantly more for the equivalent treatments than patients in the Britain and the EU.
In recent months, several large drug company projects in the UK have been halted or abandoned, while multi-billion-dollar expansions have been announced toward US facilities.
The Science Minister acknowledged that the NHS must spend more on drugs, noting that its spending on drugs had decreased as a proportion of its overall budget over the previous ten-year period.
